董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| David Arkowitz | 男 | Director | 65 | 6.84万美元 | 3.88 | 2026-10-14 |
| Gary Sender | 男 | Director | 64 | 8.84万美元 | 4.09 | 2026-10-14 |
| Martin Brenner | 男 | Chief Executive Officer, Chief Scientific Officer and Director | 55 | 213.69万美元 | 33.58 | 2026-10-14 |
| Alexandra Kropotova | 女 | Director | 53 | 7.09万美元 | 3.17 | 2026-10-14 |
| William Clark | 男 | Chairman of the Board and Director | 58 | 未披露 | 未持股 | 2026-10-14 |
| António Parada | 男 | Director | 58 | 5.84万美元 | 20.42 | 2026-10-14 |
| Elizabeth Stoner | 女 | Director | 76 | 未披露 | 未持股 | 2026-10-14 |
| Elizabeth Stoner | 女 | Director | 76 | 9.19万美元 | 0.83 | 2026-10-14 |
| William Clark | 男 | Chairman of the Board and Director | 58 | 9.84万美元 | 3.35 | 2026-10-14 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Martin Brenner | 男 | Chief Executive Officer, Chief Scientific Officer and Director | 55 | 213.69万美元 | 33.58 | 2026-10-14 |
| Felipe Duran | 男 | Chief Financial Officer | 47 | 108.13万美元 | 17.94 | 2026-10-14 |
| Marc Banjak | 男 | Chief Legal Officer | 49 | 96.65万美元 | 12.84 | 2026-10-14 |
| Molly Carr | 女 | Chief Medical Officer | 59 | 未披露 | 未持股 | 2026-10-14 |
董事简历
中英对照 | 中文 | 英文- David Arkowitz
-
David Arkowitz，2014年2月起担任董事会成员。2013年起在生物技术公司Visterra, Inc.担任首席运营官和财务总监。此前，2011年6月-2013年9月，在 Mascoma Corporation（该公司被一家生物转化公司- Lallemand, Inc.收购）担任财务总监和总经理。2007年4月-2011年5月，在一家专业医药公司-AMAG Pharmaceuticals，担任执行副总裁、财务总监和首席商务官。此前，他曾担任Idenix Pharmaceuticals, Inc.（被生物医药公司Merck & Co.，收购）的财务总监和司库。在职业生涯的早期，他曾在 Merck & Co. 工作了超过13年，包括U.S. Human Health副总裁和总会计师，以及全球研发部总会计师。2007-2009，在Aegerion Pharmaceuticals, Inc.，以及2005-2009在 ImpactRx Inc. 董事会任职。他持有Brandeis 大学的数学学士学位和Columbia 大学商学院的财务专业工商管理硕士学位。
David Arkowitz was appointed as a member of Ibio, Inc.'s Board of Directors in November 2024 and serves as a member of the Nominating and Corporate Governance Committee and the Audit Committee. Currently, Mr. Arkowitz serves as the Chief Financial Officer (CFO) of Alkeus Pharmaceuticals, a private biopharmaceutical company dedicated to preserving the sight of individuals impacted by retinal diseases. Previously he served as the CFO and Head of Business Development of publicly listed Seres Therapeutics, Inc., from June 2021 until March 2024. Previously, from May 2018 to May 2021, Mr. Arkowitz served as the CFO of Flexion Therapeutics, Inc. (acquired by Pacira BioSciences, Inc.) From September 2013 to May 2018, Mr. Arkowitz served as Chief Operating Officer and CFO at Visterra, Inc. (acquired by Otsuka Pharmaceuticals Co.) where he led the finance, business development, corporate planning and other functions. Mr. Arkowitz was CFO and General Manager at Mascoma LLC (acquired by Lallemand Inc.) from June 2011 to September 2013. Previously, Mr. Arkowitz served as CFO and Chief Business Officer at AMAG Pharmaceuticals, Inc., and CFO of Idenix Pharmaceuticals, Inc. (acquired by Merck & Co., Inc.). Prior to Idenix, Mr. Arkowitz spent more than 13 years at Merck & Co., Inc. where he held roles of increasing responsibility, including Vice President and Controller of the U.S. Human Health division and Controller of the Global Research and Development division, and CFO of the Canadian subsidiary. Mr. Arkowitz serves on the board of directors of Kineta, Inc., from December 2022 to June 2025, when it was acquired by TuHURA Biosciences and where he was a member of the audit and nominating and corporate governance committees. He has also served on the board of directors of F Star Therapeutics, Inc. from November 2020 to March 2023, where he served as the chair of the audit committee and a member of the compensation committee and Yumanity Therapeutics from December 2020 to December 2022, where he served as a member of its audit and nominating and corporate governance committees. Mr. Arkowitz earned a B.A. in Mathematics from Brandeis University and an M.B.A. in Finance from Columbia University Business School. - David Arkowitz，2014年2月起担任董事会成员。2013年起在生物技术公司Visterra, Inc.担任首席运营官和财务总监。此前，2011年6月-2013年9月，在 Mascoma Corporation（该公司被一家生物转化公司- Lallemand, Inc.收购）担任财务总监和总经理。2007年4月-2011年5月，在一家专业医药公司-AMAG Pharmaceuticals，担任执行副总裁、财务总监和首席商务官。此前，他曾担任Idenix Pharmaceuticals, Inc.（被生物医药公司Merck & Co.，收购）的财务总监和司库。在职业生涯的早期，他曾在 Merck & Co. 工作了超过13年，包括U.S. Human Health副总裁和总会计师，以及全球研发部总会计师。2007-2009，在Aegerion Pharmaceuticals, Inc.，以及2005-2009在 ImpactRx Inc. 董事会任职。他持有Brandeis 大学的数学学士学位和Columbia 大学商学院的财务专业工商管理硕士学位。
- David Arkowitz was appointed as a member of Ibio, Inc.'s Board of Directors in November 2024 and serves as a member of the Nominating and Corporate Governance Committee and the Audit Committee. Currently, Mr. Arkowitz serves as the Chief Financial Officer (CFO) of Alkeus Pharmaceuticals, a private biopharmaceutical company dedicated to preserving the sight of individuals impacted by retinal diseases. Previously he served as the CFO and Head of Business Development of publicly listed Seres Therapeutics, Inc., from June 2021 until March 2024. Previously, from May 2018 to May 2021, Mr. Arkowitz served as the CFO of Flexion Therapeutics, Inc. (acquired by Pacira BioSciences, Inc.) From September 2013 to May 2018, Mr. Arkowitz served as Chief Operating Officer and CFO at Visterra, Inc. (acquired by Otsuka Pharmaceuticals Co.) where he led the finance, business development, corporate planning and other functions. Mr. Arkowitz was CFO and General Manager at Mascoma LLC (acquired by Lallemand Inc.) from June 2011 to September 2013. Previously, Mr. Arkowitz served as CFO and Chief Business Officer at AMAG Pharmaceuticals, Inc., and CFO of Idenix Pharmaceuticals, Inc. (acquired by Merck & Co., Inc.). Prior to Idenix, Mr. Arkowitz spent more than 13 years at Merck & Co., Inc. where he held roles of increasing responsibility, including Vice President and Controller of the U.S. Human Health division and Controller of the Global Research and Development division, and CFO of the Canadian subsidiary. Mr. Arkowitz serves on the board of directors of Kineta, Inc., from December 2022 to June 2025, when it was acquired by TuHURA Biosciences and where he was a member of the audit and nominating and corporate governance committees. He has also served on the board of directors of F Star Therapeutics, Inc. from November 2020 to March 2023, where he served as the chair of the audit committee and a member of the compensation committee and Yumanity Therapeutics from December 2020 to December 2022, where he served as a member of its audit and nominating and corporate governance committees. Mr. Arkowitz earned a B.A. in Mathematics from Brandeis University and an M.B.A. in Finance from Columbia University Business School.
- Gary Sender
-
Gary Sender于2020年10月被任命为iBio, Inc.董事会成员，并于2021年12月至2022年11月10日期间担任董事会首席独立董事，当时董事会批准在任命克拉克先生为董事会主席后免去首席独立董事的职务。Sender先生目前担任审计委员会主席和薪酬委员会主席。Sender先生目前在上市公司Schrodinger, Inc.的董事会任职，并担任其审计和薪酬委员会的主席。Sender先生还在上市制药公司Harmony Biosciences Holdings, Inc.的董事会任职，并担任其审计委员会主席和薪酬委员会成员。Sender先生在上市生物技术公司Apnimed的董事会任职，是他们审计委员会的主席。Sender先生是Hula Therapeutics的董事会成员，Hula Therapeutics是一家私人控股的生物技术公司。Sender先生是一名高级管理人员和董事会成员，在大型、跨国制药和早期生物技术公司拥有超过25年的财务领导经验。2021年3月，Sender先生退休，担任Nabriva Therapeutics PLC的首席财务官，该公司是一家商业阶段的上市生物制药公司，从事治疗严重感染的创新抗感染药物的商业化和开发。他自2016年5月起担任该职位。在加入Nabriva之前，Sender先生于2015年11月至2016年4月担任协同制药公司执行副总裁兼首席财务官。在加入Synergy之前，2009年8月至2015年6月，Sender先生担任Shire plc（“Shire”）的财务高级副总裁，该公司是一家生物制药公司，自被Takeda Pharmaceutical Company Limited收购以来，为其专业制药业务以及随后的全球商业业务提供支持。在加入Shire之前，Sender先生于2004年8月至2009年7月在再生医学公司Tengion, Inc.担任首席财务官。森德先生还曾在上市制药公司默沙东公司担任多个领导职务超过15年。Sender先生获得了波士顿大学的金融学士学位和卡内基梅隆大学的工商管理硕士学位。
Gary Sender was appointed as a member of Ibio, Inc.'s Board of Directors in October 2020 and served as the Lead Independent Director of the Board of Directors from December 2021 until November 10, 2022, when the Board of Directors approved removing the role of Lead Independent Director after the appointment of Mr. Clark as the Chairperson of the Board. Mr. Sender currently serves as the Chair of the Audit Committee and as Chair of the Compensation Committee. Mr. Sender currently serves on the board of directors of Schrodinger, Inc., a publicly traded company, and is the chair of their audit and compensation committees. Mr. Sender also serves on the board of directors of Harmony Biosciences Holdings, Inc., a publicly traded pharmaceutical company, and is the chair of their audit committee and is a member of their compensation committee. Mr. Sender serves on the board of Apnimed, a publicly traded biotechnology company, and is the chair of their audit committee. Mr. Sender serves on the board of Hula Therapeutics, a privately held biotechnology company. Mr. Sender is a senior executive and board member with more than 25 years of financial leadership experience at both large, multi national pharmaceutical and early stage biotechnology companies. In March 2021, Mr. Sender retired as the Chief Financial Officer of Nabriva Therapeutics plc, a commercial stage publicly traded biopharmaceutical company engaged in the commercialization and development of innovative anti infective agents to treat serious infections. He held that position since May 2016. Prior to joining Nabriva, Mr. Sender was Executive Vice President and Chief Financial Officer of Synergy Pharmaceuticals Inc. from November 2015 to April 2016. Prior to joining Synergy, from August 2009 to June 2015, Mr. Sender served as Senior Vice President of Finance of Shire Plc's ("Shire"), a biopharmaceutical company since acquired by Takeda Pharmaceutical Company Limited supporting its Specialty Pharmaceuticals business and subsequently its Global Commercial businesses. Prior to joining Shire, Mr. Sender served as the Chief Financial Officer of Tengion, Inc., a regenerative medicine company, from August 2004 to July 2009. Mr. Sender also spent over 15 years in several leadership roles within Merck & Co. Inc., a publicly traded pharmaceutical company. Mr. Sender received a B.S. in Finance from Boston University and an M.B.A. from Carnegie Mellon University. - Gary Sender于2020年10月被任命为iBio, Inc.董事会成员，并于2021年12月至2022年11月10日期间担任董事会首席独立董事，当时董事会批准在任命克拉克先生为董事会主席后免去首席独立董事的职务。Sender先生目前担任审计委员会主席和薪酬委员会主席。Sender先生目前在上市公司Schrodinger, Inc.的董事会任职，并担任其审计和薪酬委员会的主席。Sender先生还在上市制药公司Harmony Biosciences Holdings, Inc.的董事会任职，并担任其审计委员会主席和薪酬委员会成员。Sender先生在上市生物技术公司Apnimed的董事会任职，是他们审计委员会的主席。Sender先生是Hula Therapeutics的董事会成员，Hula Therapeutics是一家私人控股的生物技术公司。Sender先生是一名高级管理人员和董事会成员，在大型、跨国制药和早期生物技术公司拥有超过25年的财务领导经验。2021年3月，Sender先生退休，担任Nabriva Therapeutics PLC的首席财务官，该公司是一家商业阶段的上市生物制药公司，从事治疗严重感染的创新抗感染药物的商业化和开发。他自2016年5月起担任该职位。在加入Nabriva之前，Sender先生于2015年11月至2016年4月担任协同制药公司执行副总裁兼首席财务官。在加入Synergy之前，2009年8月至2015年6月，Sender先生担任Shire plc（“Shire”）的财务高级副总裁，该公司是一家生物制药公司，自被Takeda Pharmaceutical Company Limited收购以来，为其专业制药业务以及随后的全球商业业务提供支持。在加入Shire之前，Sender先生于2004年8月至2009年7月在再生医学公司Tengion, Inc.担任首席财务官。森德先生还曾在上市制药公司默沙东公司担任多个领导职务超过15年。Sender先生获得了波士顿大学的金融学士学位和卡内基梅隆大学的工商管理硕士学位。
- Gary Sender was appointed as a member of Ibio, Inc.'s Board of Directors in October 2020 and served as the Lead Independent Director of the Board of Directors from December 2021 until November 10, 2022, when the Board of Directors approved removing the role of Lead Independent Director after the appointment of Mr. Clark as the Chairperson of the Board. Mr. Sender currently serves as the Chair of the Audit Committee and as Chair of the Compensation Committee. Mr. Sender currently serves on the board of directors of Schrodinger, Inc., a publicly traded company, and is the chair of their audit and compensation committees. Mr. Sender also serves on the board of directors of Harmony Biosciences Holdings, Inc., a publicly traded pharmaceutical company, and is the chair of their audit committee and is a member of their compensation committee. Mr. Sender serves on the board of Apnimed, a publicly traded biotechnology company, and is the chair of their audit committee. Mr. Sender serves on the board of Hula Therapeutics, a privately held biotechnology company. Mr. Sender is a senior executive and board member with more than 25 years of financial leadership experience at both large, multi national pharmaceutical and early stage biotechnology companies. In March 2021, Mr. Sender retired as the Chief Financial Officer of Nabriva Therapeutics plc, a commercial stage publicly traded biopharmaceutical company engaged in the commercialization and development of innovative anti infective agents to treat serious infections. He held that position since May 2016. Prior to joining Nabriva, Mr. Sender was Executive Vice President and Chief Financial Officer of Synergy Pharmaceuticals Inc. from November 2015 to April 2016. Prior to joining Synergy, from August 2009 to June 2015, Mr. Sender served as Senior Vice President of Finance of Shire Plc's ("Shire"), a biopharmaceutical company since acquired by Takeda Pharmaceutical Company Limited supporting its Specialty Pharmaceuticals business and subsequently its Global Commercial businesses. Prior to joining Shire, Mr. Sender served as the Chief Financial Officer of Tengion, Inc., a regenerative medicine company, from August 2004 to July 2009. Mr. Sender also spent over 15 years in several leadership roles within Merck & Co. Inc., a publicly traded pharmaceutical company. Mr. Sender received a B.S. in Finance from Boston University and an M.B.A. from Carnegie Mellon University.
- Martin Brenner
-
Martin Brenner自2023年6月22日起担任公司首席执行官（CEO），自2023年1月20日起担任临时首席执行官，直至其被任命为首席执行官，并自2021年1月18日起担任公司首席科学官（CSO）。Brenner博士于2024年5月9日被任命为董事会成员，自2024年6月1日起生效。Brenner博士在领导多家世界领先制药公司的药物发现和开发团队方面有着悠久的成功历史，这些公司包括阿斯利康（“阿斯利康”）、礼来 and Company（“Lilly”）、辉瑞公司（“辉瑞”）、TERM3（“TERM4”）和默沙东 Research Laboratories（“默沙东 Research Labs”）。最近，Brenner博士从2019年3月起担任Pemex Inc.的高级副总裁兼CSO，直到该公司于2020年10月被Ligand Pharmaceuticals Incorporated收购。2017年至2018年，Brenner博士在已上市的生物技术公司Recursion Pharmaceuticals, Inc.担任CSO。2016年至2017年，Brenner博士在生物技术公司Stoke Therapeutics, Inc.担任副总裁兼研究和早期开发主管。从2013年到2016年，Brenner博士在默沙东研究实验室担任糖尿病和NASH执行董事以及糖尿病和NASH早期发现部门主席。2012年至2013年，Brenner博士在阿斯利康担任CVMD高级总监、生物科学负责人。2009年至2012年，Brenner博士在辉瑞担任糖尿病预防和缓解组副研究员。从2003年到2009年，布伦纳博士担任礼来公司糖尿病药物搜寻团队的高级研究科学家。Brenner博士拥有德国汉诺威兽医学院药理学博士学位和德国慕尼黑Ludwig Maximilians大学兽医学院DVM。
Martin Brenner has served as the Company's Chief Executive Officer (CEO) since June 22, 2023, its interim CEO from January 20, 2023 until his appointment as CEO and as the Company's Chief Scientific Officer (CSO) since January 18, 2021. Dr. Brenner was appointed as a member of the Board of Directors on May 9, 2024 effective June 1, 2024. Dr. Brenner has a strong history of success heading drug discovery and development teams at several of the world's leading pharmaceutical companies, including AstraZeneca ("AstraZeneca"), Eli Lilly and Company ("Lilly"), Pfizer Inc. ("Pfizer"), and Merck Research Laboratories ("Merck Research Labs"). Most recently, Dr. Brenner served as Senior Vice President, CSO of Pemex Inc. from March 2019 until its acquisition by Ligand Pharmaceuticals Incorporated in October 2020. From 2017 to 2018, Dr. Brenner served as CSO at Recursion Pharmaceuticals, Inc., a publicly listed biotechnology company. From 2016 to 2017, Dr. Brenner served as Vice President and Head of Research and Early Development at Stoke Therapeutics, Inc., a biotechnology company. From 2013 to 2016, Dr. Brenner served as Executive Director, Diabetes & NASH, and Chair of Diabetes & NASH Early Discovery Unit at Merck Research Lab. From 2012 to 2013, Dr. Brenner served as Senior Director, Head of Bioscience, CVMD at AstraZeneca. From 2009 to 2012, Dr. Brenner served as an Associate Research Fellow for the Diabetes Prevention and Remission Group at Pfizer. From 2003 to 2009, Dr. Brenner served as Senior Research Scientist for the Diabetes Drug Hunting Team at Lilly. Dr. Brenner holds a Ph.D. in Pharmacology from the Veterinary School of Hannover in Hannover, Germany a DVM from Veterinary School of Ludwig Maximilians University in Munich, Germany. - Martin Brenner自2023年6月22日起担任公司首席执行官（CEO），自2023年1月20日起担任临时首席执行官，直至其被任命为首席执行官，并自2021年1月18日起担任公司首席科学官（CSO）。Brenner博士于2024年5月9日被任命为董事会成员，自2024年6月1日起生效。Brenner博士在领导多家世界领先制药公司的药物发现和开发团队方面有着悠久的成功历史，这些公司包括阿斯利康（“阿斯利康”）、礼来 and Company（“Lilly”）、辉瑞公司（“辉瑞”）、TERM3（“TERM4”）和默沙东 Research Laboratories（“默沙东 Research Labs”）。最近，Brenner博士从2019年3月起担任Pemex Inc.的高级副总裁兼CSO，直到该公司于2020年10月被Ligand Pharmaceuticals Incorporated收购。2017年至2018年，Brenner博士在已上市的生物技术公司Recursion Pharmaceuticals, Inc.担任CSO。2016年至2017年，Brenner博士在生物技术公司Stoke Therapeutics, Inc.担任副总裁兼研究和早期开发主管。从2013年到2016年，Brenner博士在默沙东研究实验室担任糖尿病和NASH执行董事以及糖尿病和NASH早期发现部门主席。2012年至2013年，Brenner博士在阿斯利康担任CVMD高级总监、生物科学负责人。2009年至2012年，Brenner博士在辉瑞担任糖尿病预防和缓解组副研究员。从2003年到2009年，布伦纳博士担任礼来公司糖尿病药物搜寻团队的高级研究科学家。Brenner博士拥有德国汉诺威兽医学院药理学博士学位和德国慕尼黑Ludwig Maximilians大学兽医学院DVM。
- Martin Brenner has served as the Company's Chief Executive Officer (CEO) since June 22, 2023, its interim CEO from January 20, 2023 until his appointment as CEO and as the Company's Chief Scientific Officer (CSO) since January 18, 2021. Dr. Brenner was appointed as a member of the Board of Directors on May 9, 2024 effective June 1, 2024. Dr. Brenner has a strong history of success heading drug discovery and development teams at several of the world's leading pharmaceutical companies, including AstraZeneca ("AstraZeneca"), Eli Lilly and Company ("Lilly"), Pfizer Inc. ("Pfizer"), and Merck Research Laboratories ("Merck Research Labs"). Most recently, Dr. Brenner served as Senior Vice President, CSO of Pemex Inc. from March 2019 until its acquisition by Ligand Pharmaceuticals Incorporated in October 2020. From 2017 to 2018, Dr. Brenner served as CSO at Recursion Pharmaceuticals, Inc., a publicly listed biotechnology company. From 2016 to 2017, Dr. Brenner served as Vice President and Head of Research and Early Development at Stoke Therapeutics, Inc., a biotechnology company. From 2013 to 2016, Dr. Brenner served as Executive Director, Diabetes & NASH, and Chair of Diabetes & NASH Early Discovery Unit at Merck Research Lab. From 2012 to 2013, Dr. Brenner served as Senior Director, Head of Bioscience, CVMD at AstraZeneca. From 2009 to 2012, Dr. Brenner served as an Associate Research Fellow for the Diabetes Prevention and Remission Group at Pfizer. From 2003 to 2009, Dr. Brenner served as Senior Research Scientist for the Diabetes Drug Hunting Team at Lilly. Dr. Brenner holds a Ph.D. in Pharmacology from the Veterinary School of Hannover in Hannover, Germany a DVM from Veterinary School of Ludwig Maximilians University in Munich, Germany.
- Alexandra Kropotova
-
Alexandra Kropotova于2020年10月被任命为iBio, Inc.董事会成员，目前担任董事会提名和公司治理委员会主席以及薪酬委员会成员。Kropotova博士是一名生物制药高管，在全球临床开发、转化医学和医疗事务的各个阶段都有专长。目前，Kropotova博士是SAB Biotherapeutics的执行副总裁兼首席医疗官，SAB Biotherapeutics是一家上市生物制药公司，领导公司创新多克隆抗体资产组合的战略、方向和执行。在加入SAB Biotherapeutics之前，她曾在Teva Pharmaceuticals担任全球专业研发、呼吸和炎症治疗领域副总裁，在那里她领导了全球临床开发项目的设计和执行，其中大多数是针对肺部、慢性炎症或自身免疫适应症的生物候选药物。在加入梯瓦之前，2007年至2016年间，Kropotova博士曾在赛诺菲担任过多个职务，包括副总裁、战略与战略规划主管、北美医疗事务；副副总裁兼随后的副总裁、免疫炎症、全球研发；以及呼吸、过敏和抗感染高级医疗总监。在加入赛诺菲之前，她从2002年至2007年在辉瑞公司担任过各种职务，最近担任全球临床呼吸和镇痛药物总监兼负责人。Kropotova博士在俄亥俄州雅典的俄亥俄大学商学院获得工商管理硕士学位，在俄罗斯符拉迪沃斯托克的符拉迪沃斯托克州立医科大学获得内科医学学位。
Alexandra Kropotova was appointed as a member of Ibio, Inc.'s Board of Directors in October 2020 and currently serves as Chair of the Nominating and Corporate Governance Committee of the Board of Directors and as a member of the Compensation Committee. Dr. Kropotova is a biopharmaceutical executive with expertise in all phases of global clinical development, translational medicine and medical affairs. Currently, Dr. Kropotova is Executive Vice President and Chief Medical Officer at SAb Biotherapeutics, a publicly traded biopharmaceutical company, leading the strategy, direction, and execution of the company's portfolio of innovative polyclonal antibody assets. Prior to SAb Biotherapeutics, she has served as Vice President, Global Specialty R&D, Respiratory & Inflammation Therapeutic Area at Teva Pharmaceuticals, where she led the design and execution of global clinical development programs, the majority of which are biologic candidates for pulmonary, chronic inflammatory or autoimmune indications. Prior to joining Teva, between 2007 2016, Dr. Kropotova served in various roles at Sanofi, including Vice President, Strategy & Strategic Planning Head, North American Medical Affairs; Associate Vice President and subsequently Vice President, Immuno Inflammation, Global R&D; and Senior Medical Director, Respiratory, Allergy & Anti Infectives. Prior to joining Sanofi, she served in various roles at Pfizer Inc. from 2002 2007, most recently as Director & Head of Global Clinical Respiratory and Analgesics. Dr. Kropotova received her Master of Business Administration Degree from Ohio University Graduate School of Business, Athens, Ohio, and her Medical Degree in Internal Medicine from the Vladivostok State Medical University, Vladivostok, Russia. - Alexandra Kropotova于2020年10月被任命为iBio, Inc.董事会成员，目前担任董事会提名和公司治理委员会主席以及薪酬委员会成员。Kropotova博士是一名生物制药高管，在全球临床开发、转化医学和医疗事务的各个阶段都有专长。目前，Kropotova博士是SAB Biotherapeutics的执行副总裁兼首席医疗官，SAB Biotherapeutics是一家上市生物制药公司，领导公司创新多克隆抗体资产组合的战略、方向和执行。在加入SAB Biotherapeutics之前，她曾在Teva Pharmaceuticals担任全球专业研发、呼吸和炎症治疗领域副总裁，在那里她领导了全球临床开发项目的设计和执行，其中大多数是针对肺部、慢性炎症或自身免疫适应症的生物候选药物。在加入梯瓦之前，2007年至2016年间，Kropotova博士曾在赛诺菲担任过多个职务，包括副总裁、战略与战略规划主管、北美医疗事务；副副总裁兼随后的副总裁、免疫炎症、全球研发；以及呼吸、过敏和抗感染高级医疗总监。在加入赛诺菲之前，她从2002年至2007年在辉瑞公司担任过各种职务，最近担任全球临床呼吸和镇痛药物总监兼负责人。Kropotova博士在俄亥俄州雅典的俄亥俄大学商学院获得工商管理硕士学位，在俄罗斯符拉迪沃斯托克的符拉迪沃斯托克州立医科大学获得内科医学学位。
- Alexandra Kropotova was appointed as a member of Ibio, Inc.'s Board of Directors in October 2020 and currently serves as Chair of the Nominating and Corporate Governance Committee of the Board of Directors and as a member of the Compensation Committee. Dr. Kropotova is a biopharmaceutical executive with expertise in all phases of global clinical development, translational medicine and medical affairs. Currently, Dr. Kropotova is Executive Vice President and Chief Medical Officer at SAb Biotherapeutics, a publicly traded biopharmaceutical company, leading the strategy, direction, and execution of the company's portfolio of innovative polyclonal antibody assets. Prior to SAb Biotherapeutics, she has served as Vice President, Global Specialty R&D, Respiratory & Inflammation Therapeutic Area at Teva Pharmaceuticals, where she led the design and execution of global clinical development programs, the majority of which are biologic candidates for pulmonary, chronic inflammatory or autoimmune indications. Prior to joining Teva, between 2007 2016, Dr. Kropotova served in various roles at Sanofi, including Vice President, Strategy & Strategic Planning Head, North American Medical Affairs; Associate Vice President and subsequently Vice President, Immuno Inflammation, Global R&D; and Senior Medical Director, Respiratory, Allergy & Anti Infectives. Prior to joining Sanofi, she served in various roles at Pfizer Inc. from 2002 2007, most recently as Director & Head of Global Clinical Respiratory and Analgesics. Dr. Kropotova received her Master of Business Administration Degree from Ohio University Graduate School of Business, Athens, Ohio, and her Medical Degree in Internal Medicine from the Vladivostok State Medical University, Vladivostok, Russia.
- William Clark
-
William Clark于2021年8月被任命为iBio, Inc.董事会成员，自2022年11月1日起担任董事会主席。他目前还在审计委员会任职。克拉克先生拥有30多年的生物技术和制药经验，专注于业务发展、商业化、战略规划和一般管理。目前，克拉克先生担任Altido Therapeutic的首席执行官和董事，该公司是一家私营治疗公司，旨在推动潜在的新细胞疗法治疗胶质母细胞瘤的开发。克拉克先生此前是Vibrant Biomedicines，Inc.的联合创始人，并在2024年6月至2025年6月期间担任总裁兼首席执行官。2011年至2022年，他在一家上市的生物制药公司Genocea Biosciences, Inc.（“Genocea”）担任总裁兼首席执行官。在加入Genocea之前，Clark先生是Vanda Pharmaceuticals Inc.（“万达”）的首席商务官，他于2004年与他人共同创立了这家公司。此前，他是Care Capital，LLC的负责人，这是一家投资于生物制药公司的风险投资公司。在他职业生涯的早期，他花了
William Clark was appointed as a member of Ibio, Inc.'s Board of Directors in August 2021 and has served as Chairperson of the Board since November 1, 2022. He also currently serves on the Audit Committee. Mr. Clark has more than 30 years of biotechnology and pharmaceutical experience, with a focus on business development, commercialization, strategic planning, and general management. Currently, Mr. Clark serves as the Chief Executive Officer and Director of Altido Therapeutic, a private therapeutics company formed to drive forward development of a potential new cell therapy treatment for glioblastoma. Mr. Clark previously was the Co Founder of and served as President and CEO of Vibrant Biomedicines, Inc. from June 2024 until June 2025. From 2011 until 2022, he served as the President and Chief Executive Officer of a publicly traded biopharmaceutical company, Genocea Biosciences, Inc. ("Genocea"). Prior to joining Genocea, Mr. Clark was Chief Business Officer at Vanda Pharmaceuticals Inc. ("Vanda"), a company he co founded in 2004. Previously, he was a Principal at Care Capital, LLC, a venture capital firm investing in biopharmaceutical companies. Earlier in his career, he spent - William Clark于2021年8月被任命为iBio, Inc.董事会成员，自2022年11月1日起担任董事会主席。他目前还在审计委员会任职。克拉克先生拥有30多年的生物技术和制药经验，专注于业务发展、商业化、战略规划和一般管理。目前，克拉克先生担任Altido Therapeutic的首席执行官和董事，该公司是一家私营治疗公司，旨在推动潜在的新细胞疗法治疗胶质母细胞瘤的开发。克拉克先生此前是Vibrant Biomedicines，Inc.的联合创始人，并在2024年6月至2025年6月期间担任总裁兼首席执行官。2011年至2022年，他在一家上市的生物制药公司Genocea Biosciences, Inc.（“Genocea”）担任总裁兼首席执行官。在加入Genocea之前，Clark先生是Vanda Pharmaceuticals Inc.（“万达”）的首席商务官，他于2004年与他人共同创立了这家公司。此前，他是Care Capital，LLC的负责人，这是一家投资于生物制药公司的风险投资公司。在他职业生涯的早期，他花了
- William Clark was appointed as a member of Ibio, Inc.'s Board of Directors in August 2021 and has served as Chairperson of the Board since November 1, 2022. He also currently serves on the Audit Committee. Mr. Clark has more than 30 years of biotechnology and pharmaceutical experience, with a focus on business development, commercialization, strategic planning, and general management. Currently, Mr. Clark serves as the Chief Executive Officer and Director of Altido Therapeutic, a private therapeutics company formed to drive forward development of a potential new cell therapy treatment for glioblastoma. Mr. Clark previously was the Co Founder of and served as President and CEO of Vibrant Biomedicines, Inc. from June 2024 until June 2025. From 2011 until 2022, he served as the President and Chief Executive Officer of a publicly traded biopharmaceutical company, Genocea Biosciences, Inc. ("Genocea"). Prior to joining Genocea, Mr. Clark was Chief Business Officer at Vanda Pharmaceuticals Inc. ("Vanda"), a company he co founded in 2004. Previously, he was a Principal at Care Capital, LLC, a venture capital firm investing in biopharmaceutical companies. Earlier in his career, he spent
- António Parada
-
Ant ó nio Parada于2024年11月被任命为iBio，Inc.董事会成员，目前担任提名和公司治理委员会成员。他目前是Fairjney Biologics的创始人兼首席执行官，该公司是一家私营公司，也是一家领先的抗体发现合同研究组织，为全球250多个客户提供支持，自2012年5月创立该公司以来，他一直担任这一职务。2024年6月，管理着约1500亿美元资产的全球私人市场最大公司之一Partners Group收购了FairJney的多数股权。在加入Fairjney之前，Parada先生曾于2002年至2013年担任葡萄牙Porta的Instituto de Biologia Molecular e Celular（IBMC）总经理。从2011年2月至2012年5月，Parada先生担任IPO Porto –葡萄牙波尔图肿瘤医院临床试验部门的经理。从2008年6月到2012年3月，Parada先生是Ablynx’（赛诺菲 S.A.的子公司）位于葡萄牙Portal的“噬菌体显示卓越中心”的现场经理。2002年6月，帕拉达先生创立了咨询公司BioCodex Group，并担任首席执行官直到2008年12月，该公司的营业额约为1000万欧元。Parada先生于2014年5月至2017年5月期间担任Centro de Diagn ó stico y Estudios Metab ó licos Avanzados de Cantabria（CDEMAC）的董事会成员，现任EMBLEM监事会主席，自2011年1月起担任该职务。帕拉达先生有15篇关于药理学的同行复刊jnals和其他几篇关于植物学、管理、营销和安全的出版物，并持有葡萄牙波尔图市的功绩勋章和葡萄牙马托西尼奥斯市的事业奖。Parada先生毕业于葡萄牙波尔图大学，拥有葡萄牙天主教大学MBA学位。
António Parada was appointed as a member of iBio, Inc. Board of Directors in November 2024 and currently serves as a member of the Nominating and Corporate Governance Committee. He is currently the Founder and CEO of Fairjney Biologics, a privately held company and a leading antibody discovery contract research organization supporting more than 250 clients across the globe, a role he has held since founding the company in May 2012. In June 2024, the Partners Group, one of the largest firms in the global private markets industry with approximately $150 billion in assets under management, acquired a majority ownership in FairJney. Prior to Fairjney, Mr. Parada was the General Manager of Instituto de Biologia Molecular e Celular (IBMC), in Porta, Portugal, from 2002 until 2013. From February 2011 until May 2012, Mr. Parada was the Manager of the Clinical Trial Unit of IPO Porto – Cancer Hospital in Porto, Portugal. From June 2008 to March 2012, Mr. Parada was the Site Manager of Ablynx' (a subsidiary of Sanofi S.A.) "Centre of Excellence in Phage Display" located in Portal, Portugal. In June 2002, Mr. Parada founded the BioCodex Group, a consulting firm, and was the CEO until December 2008, which firm had a turnover of approximately 10 million Euros. Mr. Parada was a Board Member of Centro de Diagnóstico y Estudios Metabólicos Avanzados de Cantabria (CDEMAC) from May 2014 until May 2017 and is currently the Chairman of the Supervisory Board of EMBLEM, a position he has held since January 2011. Mr. Parada has 15 publications in peer revied jnals on pharmacology and several others in botany, management, marketing and security and holds the medal of Merit of the city of Porto, Portugal and career award of the city of Matosinhos, Portugal. Mr. Parada graduated from the University of Porto, Portugal and has a MBA from the Portuguese Catholic University. - Ant ó nio Parada于2024年11月被任命为iBio，Inc.董事会成员，目前担任提名和公司治理委员会成员。他目前是Fairjney Biologics的创始人兼首席执行官，该公司是一家私营公司，也是一家领先的抗体发现合同研究组织，为全球250多个客户提供支持，自2012年5月创立该公司以来，他一直担任这一职务。2024年6月，管理着约1500亿美元资产的全球私人市场最大公司之一Partners Group收购了FairJney的多数股权。在加入Fairjney之前，Parada先生曾于2002年至2013年担任葡萄牙Porta的Instituto de Biologia Molecular e Celular（IBMC）总经理。从2011年2月至2012年5月，Parada先生担任IPO Porto –葡萄牙波尔图肿瘤医院临床试验部门的经理。从2008年6月到2012年3月，Parada先生是Ablynx’（赛诺菲 S.A.的子公司）位于葡萄牙Portal的“噬菌体显示卓越中心”的现场经理。2002年6月，帕拉达先生创立了咨询公司BioCodex Group，并担任首席执行官直到2008年12月，该公司的营业额约为1000万欧元。Parada先生于2014年5月至2017年5月期间担任Centro de Diagn ó stico y Estudios Metab ó licos Avanzados de Cantabria（CDEMAC）的董事会成员，现任EMBLEM监事会主席，自2011年1月起担任该职务。帕拉达先生有15篇关于药理学的同行复刊jnals和其他几篇关于植物学、管理、营销和安全的出版物，并持有葡萄牙波尔图市的功绩勋章和葡萄牙马托西尼奥斯市的事业奖。Parada先生毕业于葡萄牙波尔图大学，拥有葡萄牙天主教大学MBA学位。
- António Parada was appointed as a member of iBio, Inc. Board of Directors in November 2024 and currently serves as a member of the Nominating and Corporate Governance Committee. He is currently the Founder and CEO of Fairjney Biologics, a privately held company and a leading antibody discovery contract research organization supporting more than 250 clients across the globe, a role he has held since founding the company in May 2012. In June 2024, the Partners Group, one of the largest firms in the global private markets industry with approximately $150 billion in assets under management, acquired a majority ownership in FairJney. Prior to Fairjney, Mr. Parada was the General Manager of Instituto de Biologia Molecular e Celular (IBMC), in Porta, Portugal, from 2002 until 2013. From February 2011 until May 2012, Mr. Parada was the Manager of the Clinical Trial Unit of IPO Porto – Cancer Hospital in Porto, Portugal. From June 2008 to March 2012, Mr. Parada was the Site Manager of Ablynx' (a subsidiary of Sanofi S.A.) "Centre of Excellence in Phage Display" located in Portal, Portugal. In June 2002, Mr. Parada founded the BioCodex Group, a consulting firm, and was the CEO until December 2008, which firm had a turnover of approximately 10 million Euros. Mr. Parada was a Board Member of Centro de Diagnóstico y Estudios Metabólicos Avanzados de Cantabria (CDEMAC) from May 2014 until May 2017 and is currently the Chairman of the Supervisory Board of EMBLEM, a position he has held since January 2011. Mr. Parada has 15 publications in peer revied jnals on pharmacology and several others in botany, management, marketing and security and holds the medal of Merit of the city of Porto, Portugal and career award of the city of Matosinhos, Portugal. Mr. Parada graduated from the University of Porto, Portugal and has a MBA from the Portuguese Catholic University.
- Elizabeth Stoner
-
Elizabeth Stoner于2026年5月被任命为iBio, Inc.董事会成员，目前担任薪酬委员会成员。Stoner博士目前是MPM BioImpact的企业家合伙人，为私人和公共基金提供支持。Stoner博士曾在MPM BioImpact投资组合公司担任过多个领导职务，包括Semma Therapeutics的临时首席执行官；以及Rhythm Pharmaceuticals, Inc.的创始人、首席医疗官和首席开发官。她还曾在Clinical Ink，Inc.、Potenza Therapeutics，Inc.、Solasia Pharma、Werewolf Therapeutics Inc.和TriNetX，LLC担任临床和咨询职务。在加入MPM BioImpact之前，Stoner博士是默沙东研究实验室全球临床开发运营高级副总裁，负责该实验室在40多个国家的临床开发活动。在加入默沙东研究实验室之前，她是康奈尔大学医学院儿科助理教授。Stoner博士目前担任两家私营、临床阶段生物制药公司的董事会成员，LIB Therapeutics自2016年起担任，Antiva Bioscience自2023年起担任。2021年11月至2026年2月，她还担任Arovella Therapeutics Ltd.的董事会成员，该公司是一家在澳大利亚证券交易所上市的生物技术公司。斯托纳博士获得了阿尔伯特·爱因斯坦医学院的医学博士学位、纽约州石溪的SUNY的化学硕士学位和堪萨斯州渥太华大学的化学学士学位。
Elizabeth Stoner was appointed as a member of Ibio, Inc.'s Board of Directors in May 2026 and currently serves as a member of the Compensation Committee. Dr. Stoner is currently an Entrepreneur Partner at MPM BioImpact, supporting both private and public funds. Dr. Stoner has held several leadership roles at MPM BioImpact portfolio companies including interim Chief Executive Officer of Semma Therapeutics; and founder, Chief Medical Officer and Chief Development Officer of Rhythm Pharmaceuticals, Inc. She also served in clinical and advisory roles at Clinical Ink, Inc., Potenza Therapeutics, Inc., Solasia Pharma, Werewolf Therapeutics Inc., and TriNetX, LLC. Prior to joining MPM BioImpact, Dr. Stoner was Senior Vice President of Global Clinical Development Operations at Merck Research Laboratories where she was responsible for its clinical development activities in more than 40 countries. Prior to joining the Merck Research Laboratories, she was an Assistant Professor of Pediatrics at Cornell University Medical College. Dr. Stoner currently serves as a member of the board of two privately held, clinical stage biopharmaceutical companies, LIB Therapeutics, since 2016, and Antiva Bioscience, since 2023. She also served as a member of the board of Arovella Therapeutics Ltd., a biotechnology company traded on the Australian Securities Exchange, from November 2021 until February 2026. Dr. Stoner received her M.D. from the Albert Einstein College of Medicine, M.S. in Chemistry from SUNY at Stony Brook, New York and B.S. in Chemistry from Ottawa University, Kansas. - Elizabeth Stoner于2026年5月被任命为iBio, Inc.董事会成员，目前担任薪酬委员会成员。Stoner博士目前是MPM BioImpact的企业家合伙人，为私人和公共基金提供支持。Stoner博士曾在MPM BioImpact投资组合公司担任过多个领导职务，包括Semma Therapeutics的临时首席执行官；以及Rhythm Pharmaceuticals, Inc.的创始人、首席医疗官和首席开发官。她还曾在Clinical Ink，Inc.、Potenza Therapeutics，Inc.、Solasia Pharma、Werewolf Therapeutics Inc.和TriNetX，LLC担任临床和咨询职务。在加入MPM BioImpact之前，Stoner博士是默沙东研究实验室全球临床开发运营高级副总裁，负责该实验室在40多个国家的临床开发活动。在加入默沙东研究实验室之前，她是康奈尔大学医学院儿科助理教授。Stoner博士目前担任两家私营、临床阶段生物制药公司的董事会成员，LIB Therapeutics自2016年起担任，Antiva Bioscience自2023年起担任。2021年11月至2026年2月，她还担任Arovella Therapeutics Ltd.的董事会成员，该公司是一家在澳大利亚证券交易所上市的生物技术公司。斯托纳博士获得了阿尔伯特·爱因斯坦医学院的医学博士学位、纽约州石溪的SUNY的化学硕士学位和堪萨斯州渥太华大学的化学学士学位。
- Elizabeth Stoner was appointed as a member of Ibio, Inc.'s Board of Directors in May 2026 and currently serves as a member of the Compensation Committee. Dr. Stoner is currently an Entrepreneur Partner at MPM BioImpact, supporting both private and public funds. Dr. Stoner has held several leadership roles at MPM BioImpact portfolio companies including interim Chief Executive Officer of Semma Therapeutics; and founder, Chief Medical Officer and Chief Development Officer of Rhythm Pharmaceuticals, Inc. She also served in clinical and advisory roles at Clinical Ink, Inc., Potenza Therapeutics, Inc., Solasia Pharma, Werewolf Therapeutics Inc., and TriNetX, LLC. Prior to joining MPM BioImpact, Dr. Stoner was Senior Vice President of Global Clinical Development Operations at Merck Research Laboratories where she was responsible for its clinical development activities in more than 40 countries. Prior to joining the Merck Research Laboratories, she was an Assistant Professor of Pediatrics at Cornell University Medical College. Dr. Stoner currently serves as a member of the board of two privately held, clinical stage biopharmaceutical companies, LIB Therapeutics, since 2016, and Antiva Bioscience, since 2023. She also served as a member of the board of Arovella Therapeutics Ltd., a biotechnology company traded on the Australian Securities Exchange, from November 2021 until February 2026. Dr. Stoner received her M.D. from the Albert Einstein College of Medicine, M.S. in Chemistry from SUNY at Stony Brook, New York and B.S. in Chemistry from Ottawa University, Kansas.
- Elizabeth Stoner
-
Elizabeth Stoner， 医学博士。2011年5月起，她担任公司董事会成员；2007年10月起，担任MPM Capital的总经理；2010年起，担任生物技术公司Rhythm Pharmaceuticals的首席发展官。加入MPM Capital前， 她担任多职，包括1985年起，担任Merck Research Laboratories全球临床研发运营的高级副总裁。她目前Momenta Pharmaceuticals Inc.的董事， 2009至2010年，担任Metabasis Therapeutics, Inc.的董事。她在Albert Einstein College of Medicine获得医学博士学位，在纽约州立大学（State University of New York）斯托尼布鲁克分校获得化学学士学位，在堪萨斯州渥太华大学（Ottawa University）获得化学学士学位。
Elizabeth Stoner, M.D., has been a director since October 2007. Since September 2012 Dr. Stoner has been the chief development officer at Vascular Pharmaceuticals, Inc., a biotechnology company. From 2010 to 2014 Dr. Stoner was the chief development officer of Rhythm Pharmaceuticals, and since December 2014 she has been a member of Rhythm's Scientific Advisory Board. Since October 2007 Dr. Stoner has served as a managing director at MPM Capital, a healthcare venture capital firm. Prior to joining MPM Capital, Dr. Stoner had a distinguished 22-year career at Merck Research Laboratories. At the time of her retirement from Merck, Dr. Stoner was senior vice president of Global Clinical Development Operations with responsibility for the company's clinical development activities in more than 40 countries, including Merck's Japanese subsidiary. Prior to her position at Merck, she was an assistant professor of Pediatrics at Cornell University Medical College. Dr. Stoner served on the board of Radius Health, Inc. from 2011 to 2015. Dr. Stoner received her B.S. in Chemistry from Ottawa University, KS, her M.S. in Chemistry from the State University of New York at Stony Brook, and her M.D. from Albert Einstein College of Medicine. - Elizabeth Stoner， 医学博士。2011年5月起，她担任公司董事会成员；2007年10月起，担任MPM Capital的总经理；2010年起，担任生物技术公司Rhythm Pharmaceuticals的首席发展官。加入MPM Capital前， 她担任多职，包括1985年起，担任Merck Research Laboratories全球临床研发运营的高级副总裁。她目前Momenta Pharmaceuticals Inc.的董事， 2009至2010年，担任Metabasis Therapeutics, Inc.的董事。她在Albert Einstein College of Medicine获得医学博士学位，在纽约州立大学（State University of New York）斯托尼布鲁克分校获得化学学士学位，在堪萨斯州渥太华大学（Ottawa University）获得化学学士学位。
- Elizabeth Stoner, M.D., has been a director since October 2007. Since September 2012 Dr. Stoner has been the chief development officer at Vascular Pharmaceuticals, Inc., a biotechnology company. From 2010 to 2014 Dr. Stoner was the chief development officer of Rhythm Pharmaceuticals, and since December 2014 she has been a member of Rhythm's Scientific Advisory Board. Since October 2007 Dr. Stoner has served as a managing director at MPM Capital, a healthcare venture capital firm. Prior to joining MPM Capital, Dr. Stoner had a distinguished 22-year career at Merck Research Laboratories. At the time of her retirement from Merck, Dr. Stoner was senior vice president of Global Clinical Development Operations with responsibility for the company's clinical development activities in more than 40 countries, including Merck's Japanese subsidiary. Prior to her position at Merck, she was an assistant professor of Pediatrics at Cornell University Medical College. Dr. Stoner served on the board of Radius Health, Inc. from 2011 to 2015. Dr. Stoner received her B.S. in Chemistry from Ottawa University, KS, her M.S. in Chemistry from the State University of New York at Stony Brook, and her M.D. from Albert Einstein College of Medicine.
- William Clark
-
William Clark，自2011年2月起，他一直担任总裁和首席执行官。自2010年8月至2011年2月，他担任首席商务官。自2011年2月起，他任职于董事会。在加入公司之前，他担任Vanda Pharmaceuticals, Inc.的首席商务官，这是一个他于2004年联合创立的生物制药公司；在该公司任职时，他领导公司的战略和业务开发活动，在筹集超过2.2亿美元的多元化公开和私人融资活动中起到了核心作用。在加入Vanda 之前，在 SmithKline Beecham （即现在的 GlaxoSmithKline）担任过许多商业和战略方面的职务之后，他担任Care Capital, LLC（这是一个风险投资公司，投资于生物制药公司。）的负责人。他持有Harvard University的学士学位， the University of Pennsylvania沃顿商学院的工商管理学硕士学位。
William Clark has served as President and Chief Executive Officer since February 2011 after serving as Chief Business Officer from August 2010 to February 2011. Chip has also served on board of directors since February 2011. Prior to joining Genocea, he served as Chief Business Officer at Vanda Pharmaceuticals, a biopharmaceutical company he co-founded in 2004. While at Vanda, he led the company's strategic and business development activities and played a central role in raising more than $400 million through business development deals and equity financings. Prior to Vanda, Chip was a principal at Care Capital, a venture capital firm investing in biopharmaceutical companies, after serving in a variety of commercial and strategic roles at SmithKline Beecham now GlaxoSmithKline. Chip holds a B.A. from Harvard University and an M.B.A. from The Wharton School at the University of Pennsylvania. - William Clark，自2011年2月起，他一直担任总裁和首席执行官。自2010年8月至2011年2月，他担任首席商务官。自2011年2月起，他任职于董事会。在加入公司之前，他担任Vanda Pharmaceuticals, Inc.的首席商务官，这是一个他于2004年联合创立的生物制药公司；在该公司任职时，他领导公司的战略和业务开发活动，在筹集超过2.2亿美元的多元化公开和私人融资活动中起到了核心作用。在加入Vanda 之前，在 SmithKline Beecham （即现在的 GlaxoSmithKline）担任过许多商业和战略方面的职务之后，他担任Care Capital, LLC（这是一个风险投资公司，投资于生物制药公司。）的负责人。他持有Harvard University的学士学位， the University of Pennsylvania沃顿商学院的工商管理学硕士学位。
- William Clark has served as President and Chief Executive Officer since February 2011 after serving as Chief Business Officer from August 2010 to February 2011. Chip has also served on board of directors since February 2011. Prior to joining Genocea, he served as Chief Business Officer at Vanda Pharmaceuticals, a biopharmaceutical company he co-founded in 2004. While at Vanda, he led the company's strategic and business development activities and played a central role in raising more than $400 million through business development deals and equity financings. Prior to Vanda, Chip was a principal at Care Capital, a venture capital firm investing in biopharmaceutical companies, after serving in a variety of commercial and strategic roles at SmithKline Beecham now GlaxoSmithKline. Chip holds a B.A. from Harvard University and an M.B.A. from The Wharton School at the University of Pennsylvania.
高管简历
中英对照 | 中文 | 英文- Martin Brenner
Martin Brenner自2023年6月22日起担任公司首席执行官（CEO），自2023年1月20日起担任临时首席执行官，直至其被任命为首席执行官，并自2021年1月18日起担任公司首席科学官（CSO）。Brenner博士于2024年5月9日被任命为董事会成员，自2024年6月1日起生效。Brenner博士在领导多家世界领先制药公司的药物发现和开发团队方面有着悠久的成功历史，这些公司包括阿斯利康（“阿斯利康”）、礼来 and Company（“Lilly”）、辉瑞公司（“辉瑞”）、TERM3（“TERM4”）和默沙东 Research Laboratories（“默沙东 Research Labs”）。最近，Brenner博士从2019年3月起担任Pemex Inc.的高级副总裁兼CSO，直到该公司于2020年10月被Ligand Pharmaceuticals Incorporated收购。2017年至2018年，Brenner博士在已上市的生物技术公司Recursion Pharmaceuticals, Inc.担任CSO。2016年至2017年，Brenner博士在生物技术公司Stoke Therapeutics, Inc.担任副总裁兼研究和早期开发主管。从2013年到2016年，Brenner博士在默沙东研究实验室担任糖尿病和NASH执行董事以及糖尿病和NASH早期发现部门主席。2012年至2013年，Brenner博士在阿斯利康担任CVMD高级总监、生物科学负责人。2009年至2012年，Brenner博士在辉瑞担任糖尿病预防和缓解组副研究员。从2003年到2009年，布伦纳博士担任礼来公司糖尿病药物搜寻团队的高级研究科学家。Brenner博士拥有德国汉诺威兽医学院药理学博士学位和德国慕尼黑Ludwig Maximilians大学兽医学院DVM。
Martin Brenner has served as the Company's Chief Executive Officer (CEO) since June 22, 2023, its interim CEO from January 20, 2023 until his appointment as CEO and as the Company's Chief Scientific Officer (CSO) since January 18, 2021. Dr. Brenner was appointed as a member of the Board of Directors on May 9, 2024 effective June 1, 2024. Dr. Brenner has a strong history of success heading drug discovery and development teams at several of the world's leading pharmaceutical companies, including AstraZeneca ("AstraZeneca"), Eli Lilly and Company ("Lilly"), Pfizer Inc. ("Pfizer"), and Merck Research Laboratories ("Merck Research Labs"). Most recently, Dr. Brenner served as Senior Vice President, CSO of Pemex Inc. from March 2019 until its acquisition by Ligand Pharmaceuticals Incorporated in October 2020. From 2017 to 2018, Dr. Brenner served as CSO at Recursion Pharmaceuticals, Inc., a publicly listed biotechnology company. From 2016 to 2017, Dr. Brenner served as Vice President and Head of Research and Early Development at Stoke Therapeutics, Inc., a biotechnology company. From 2013 to 2016, Dr. Brenner served as Executive Director, Diabetes & NASH, and Chair of Diabetes & NASH Early Discovery Unit at Merck Research Lab. From 2012 to 2013, Dr. Brenner served as Senior Director, Head of Bioscience, CVMD at AstraZeneca. From 2009 to 2012, Dr. Brenner served as an Associate Research Fellow for the Diabetes Prevention and Remission Group at Pfizer. From 2003 to 2009, Dr. Brenner served as Senior Research Scientist for the Diabetes Drug Hunting Team at Lilly. Dr. Brenner holds a Ph.D. in Pharmacology from the Veterinary School of Hannover in Hannover, Germany a DVM from Veterinary School of Ludwig Maximilians University in Munich, Germany.- Martin Brenner自2023年6月22日起担任公司首席执行官（CEO），自2023年1月20日起担任临时首席执行官，直至其被任命为首席执行官，并自2021年1月18日起担任公司首席科学官（CSO）。Brenner博士于2024年5月9日被任命为董事会成员，自2024年6月1日起生效。Brenner博士在领导多家世界领先制药公司的药物发现和开发团队方面有着悠久的成功历史，这些公司包括阿斯利康（“阿斯利康”）、礼来 and Company（“Lilly”）、辉瑞公司（“辉瑞”）、TERM3（“TERM4”）和默沙东 Research Laboratories（“默沙东 Research Labs”）。最近，Brenner博士从2019年3月起担任Pemex Inc.的高级副总裁兼CSO，直到该公司于2020年10月被Ligand Pharmaceuticals Incorporated收购。2017年至2018年，Brenner博士在已上市的生物技术公司Recursion Pharmaceuticals, Inc.担任CSO。2016年至2017年，Brenner博士在生物技术公司Stoke Therapeutics, Inc.担任副总裁兼研究和早期开发主管。从2013年到2016年，Brenner博士在默沙东研究实验室担任糖尿病和NASH执行董事以及糖尿病和NASH早期发现部门主席。2012年至2013年，Brenner博士在阿斯利康担任CVMD高级总监、生物科学负责人。2009年至2012年，Brenner博士在辉瑞担任糖尿病预防和缓解组副研究员。从2003年到2009年，布伦纳博士担任礼来公司糖尿病药物搜寻团队的高级研究科学家。Brenner博士拥有德国汉诺威兽医学院药理学博士学位和德国慕尼黑Ludwig Maximilians大学兽医学院DVM。
- Martin Brenner has served as the Company's Chief Executive Officer (CEO) since June 22, 2023, its interim CEO from January 20, 2023 until his appointment as CEO and as the Company's Chief Scientific Officer (CSO) since January 18, 2021. Dr. Brenner was appointed as a member of the Board of Directors on May 9, 2024 effective June 1, 2024. Dr. Brenner has a strong history of success heading drug discovery and development teams at several of the world's leading pharmaceutical companies, including AstraZeneca ("AstraZeneca"), Eli Lilly and Company ("Lilly"), Pfizer Inc. ("Pfizer"), and Merck Research Laboratories ("Merck Research Labs"). Most recently, Dr. Brenner served as Senior Vice President, CSO of Pemex Inc. from March 2019 until its acquisition by Ligand Pharmaceuticals Incorporated in October 2020. From 2017 to 2018, Dr. Brenner served as CSO at Recursion Pharmaceuticals, Inc., a publicly listed biotechnology company. From 2016 to 2017, Dr. Brenner served as Vice President and Head of Research and Early Development at Stoke Therapeutics, Inc., a biotechnology company. From 2013 to 2016, Dr. Brenner served as Executive Director, Diabetes & NASH, and Chair of Diabetes & NASH Early Discovery Unit at Merck Research Lab. From 2012 to 2013, Dr. Brenner served as Senior Director, Head of Bioscience, CVMD at AstraZeneca. From 2009 to 2012, Dr. Brenner served as an Associate Research Fellow for the Diabetes Prevention and Remission Group at Pfizer. From 2003 to 2009, Dr. Brenner served as Senior Research Scientist for the Diabetes Drug Hunting Team at Lilly. Dr. Brenner holds a Ph.D. in Pharmacology from the Veterinary School of Hannover in Hannover, Germany a DVM from Veterinary School of Ludwig Maximilians University in Munich, Germany.
- Felipe Duran
Felipe Duran自2023年6月起担任iBio的首席财务官（CFO），在此之前，自2023年1月20日起担任iBio的临时CFO，此前自2021年5月起担任iBio的财务规划和分析（FP & A）副总裁。此前，Duran先生曾于2016年5月至2021年5月担任Lupin Pharmaceuticals的子公司Lupin Latin America的执行董事（CFO），负责监督该地区和美国研发财务组织的财务、IT和供应链。此前，Duran先生于2016年5月至2021年5月期间担任Lupin Pharmaceuticals子公司Lupin Latin America的执行董事（CFO）。在担任这一职务期间，杜兰先生负责拉丁美洲的金融、IT和供应链。此外，杜兰先生还负责美国研发金融组织。在加入Lupin Pharmaceuticals之前，Duran先生在Teva Pharmaceuticals的增长市场和拉丁美洲地区担任过多个战略职位。在其职业生涯的早期，Duran先生曾在英国联合公积金协会有限公司（BUPA）、一家多国健康保险和医疗保健公司、Noven Pharmaceuticals，Inc.、Bayview Asset Management，LLC.、HIG资本和IBM公司担任FP & A和其他与金融相关的职务。Duran先生获得了迈阿密大学的金融学士学位和工商管理硕士学位。
Felipe Duran has been iBio's Chief Financial Officer (CFO) since June 2023 and prior thereto from January 20, 2023 he served as iBio's interim CFO, and previously as iBio's Vice President of Financial Planning and Analysis (FP&A) from May 2021. Previously, Mr. Duran served as the Executive Director (CFO), of Lupin Latin America, a subsidiary of Lupin Pharmaceuticals, overseeing finance, IT and supply chain for the region and for the US R&D finance organization, from May 2016 to May 2021. Previously, Mr. Duran served as the Executive Director (CFO), of Lupin Latin America, a subsidiary of Lupin Pharmaceuticals, from May 2016 – May 2021. In this role, Mr. Duran was responsible for finance, IT and supply chain for Latin America. Additionally, Mr. Duran was responsible for the US R&D finance organization. Prior to joining Lupin Pharmaceuticals, Mr. Duran held various strategic positions at Teva Pharmaceuticals in both its growth markets and Latin America regions. Earlier in his career, Mr. Duran held FP&A and other financial related roles with British United Provident Association Limited (BUPA), a multi national health insurance and healthcare company, Noven Pharmaceuticals, Inc., Bayview Asset Management, LLC., HIG Capital and IBM Corporation. Mr. Duran received a B.A. in Finance and an M.B.A from the University of Miami.- Felipe Duran自2023年6月起担任iBio的首席财务官（CFO），在此之前，自2023年1月20日起担任iBio的临时CFO，此前自2021年5月起担任iBio的财务规划和分析（FP & A）副总裁。此前，Duran先生曾于2016年5月至2021年5月担任Lupin Pharmaceuticals的子公司Lupin Latin America的执行董事（CFO），负责监督该地区和美国研发财务组织的财务、IT和供应链。此前，Duran先生于2016年5月至2021年5月期间担任Lupin Pharmaceuticals子公司Lupin Latin America的执行董事（CFO）。在担任这一职务期间，杜兰先生负责拉丁美洲的金融、IT和供应链。此外，杜兰先生还负责美国研发金融组织。在加入Lupin Pharmaceuticals之前，Duran先生在Teva Pharmaceuticals的增长市场和拉丁美洲地区担任过多个战略职位。在其职业生涯的早期，Duran先生曾在英国联合公积金协会有限公司（BUPA）、一家多国健康保险和医疗保健公司、Noven Pharmaceuticals，Inc.、Bayview Asset Management，LLC.、HIG资本和IBM公司担任FP & A和其他与金融相关的职务。Duran先生获得了迈阿密大学的金融学士学位和工商管理硕士学位。
- Felipe Duran has been iBio's Chief Financial Officer (CFO) since June 2023 and prior thereto from January 20, 2023 he served as iBio's interim CFO, and previously as iBio's Vice President of Financial Planning and Analysis (FP&A) from May 2021. Previously, Mr. Duran served as the Executive Director (CFO), of Lupin Latin America, a subsidiary of Lupin Pharmaceuticals, overseeing finance, IT and supply chain for the region and for the US R&D finance organization, from May 2016 to May 2021. Previously, Mr. Duran served as the Executive Director (CFO), of Lupin Latin America, a subsidiary of Lupin Pharmaceuticals, from May 2016 – May 2021. In this role, Mr. Duran was responsible for finance, IT and supply chain for Latin America. Additionally, Mr. Duran was responsible for the US R&D finance organization. Prior to joining Lupin Pharmaceuticals, Mr. Duran held various strategic positions at Teva Pharmaceuticals in both its growth markets and Latin America regions. Earlier in his career, Mr. Duran held FP&A and other financial related roles with British United Provident Association Limited (BUPA), a multi national health insurance and healthcare company, Noven Pharmaceuticals, Inc., Bayview Asset Management, LLC., HIG Capital and IBM Corporation. Mr. Duran received a B.A. in Finance and an M.B.A from the University of Miami.
- Marc Banjak
Marc Banjak自2024年8月起担任iBio的首席法务官（CLO），在此之前自2022年2月21日起担任iBio的总法律顾问和公司秘书。Banjak先生此前曾于2021年4月至9月担任私营公司Istari Oncology的首任总法律顾问，并于2017年10月至2021年4月担任当时的上市公司Dova制药的首任总法律顾问，领导这两个组织内的法律和合规职能。在Dova任职期间，Banjak先生通过瑞典Orphan Biovitrum AB收购Dova为公司提供咨询服务。在此之前，Banjak先生曾在PRA健康科学、B.博朗医疗、PPD担任律师。在进入生物技术和合同研究行业之前，班贾克曾在美国空军担任现役军官，担任过各种法律职务。班贾克先生被科罗拉多州律师协会录取。Banjak先生在丹佛大学法学院获得了京东学位，在富兰克林和马歇尔学院获得了心理学学士学位。
Marc Banjak has been iBio's Chief Legal Officer (CLO) since August 2024 and prior thereto from February 21, 2022 he served as iBio's General Counsel and Corporate Secretary. Mr. Banjak previously served as the first general counsel of both Istari Oncology, a privately held company, from April to September 2021, and Dova Pharmaceuticals, then a publicly traded company, leading the legal and compliance functions within both organizations, from October 2017 to April 2021. While at Dova, Mr. Banjak advised the company through the acquisition of Dova by Swedish Orphan Biovitrum AB. Prior to that, Mr. Banjak worked as an attorney at PRA Health Sciences, B. Braun Medical, and PPD. Prior to entering the biotechnology and contract research industries, Mr. Banjak served as an active duty officer in the U.S. Air Force in a variety of legal roles. Mr. Banjak is admitted to the Colorado State Bar. Mr. Banjak earned his JD from the University of Denver School of Law and a BA in Psychology from Franklin and Marshall College.- Marc Banjak自2024年8月起担任iBio的首席法务官（CLO），在此之前自2022年2月21日起担任iBio的总法律顾问和公司秘书。Banjak先生此前曾于2021年4月至9月担任私营公司Istari Oncology的首任总法律顾问，并于2017年10月至2021年4月担任当时的上市公司Dova制药的首任总法律顾问，领导这两个组织内的法律和合规职能。在Dova任职期间，Banjak先生通过瑞典Orphan Biovitrum AB收购Dova为公司提供咨询服务。在此之前，Banjak先生曾在PRA健康科学、B.博朗医疗、PPD担任律师。在进入生物技术和合同研究行业之前，班贾克曾在美国空军担任现役军官，担任过各种法律职务。班贾克先生被科罗拉多州律师协会录取。Banjak先生在丹佛大学法学院获得了京东学位，在富兰克林和马歇尔学院获得了心理学学士学位。
- Marc Banjak has been iBio's Chief Legal Officer (CLO) since August 2024 and prior thereto from February 21, 2022 he served as iBio's General Counsel and Corporate Secretary. Mr. Banjak previously served as the first general counsel of both Istari Oncology, a privately held company, from April to September 2021, and Dova Pharmaceuticals, then a publicly traded company, leading the legal and compliance functions within both organizations, from October 2017 to April 2021. While at Dova, Mr. Banjak advised the company through the acquisition of Dova by Swedish Orphan Biovitrum AB. Prior to that, Mr. Banjak worked as an attorney at PRA Health Sciences, B. Braun Medical, and PPD. Prior to entering the biotechnology and contract research industries, Mr. Banjak served as an active duty officer in the U.S. Air Force in a variety of legal roles. Mr. Banjak is admitted to the Colorado State Bar. Mr. Banjak earned his JD from the University of Denver School of Law and a BA in Psychology from Franklin and Marshall College.
- Molly Carr
Molly Carr自2026年7月起担任iBio, Inc.的首席医疗官，是一名医师主管，在生物技术和制药行业拥有丰富经验。就在加入公司之前，她自2021年起在礼来公司担任胰岛素和胰高血糖素特许经营临床主管、副总裁。在担任该职务期间，她负责监督礼来公司胰岛素和胰高血糖素产品组合的临床开发活动，包括每周一次的胰岛素候选药物efitora的后期开发项目，以及其他糖尿病和代谢性疾病疗法。在担任该职位之前，Carr博士曾于2018年至2021年在礼来公司担任高级医学研究员、糖尿病业务发展和外部创新副总裁，在那里她领导了外部业务发展机会的评估，并支持糖尿病和相关代谢疾病的许可和战略交易。在加入礼来之前，Carl博士在葛兰素史克公司担任的职务越来越重要，包括内分泌科学主管、代谢途径和心血管研发部门，以及阿必鲁肽全球医疗事务主管。在她职业生涯的早期，她曾在CSL Behring和Wyeth LLC担任临床开发和医学领导职务，并在西北大学、华盛顿大学和宾夕法尼亚大学担任内分泌学和新陈代谢领域的学术职务。卡尔博士获得了巴纳德学院的生物学学士学位和哥伦比亚内科医生和外科医生学院的医学博士学位。她获得了内分泌学、糖尿病和代谢以及内科的董事会认证。
Molly Carr has served as Ibio, Inc.'s Chief Medical Officer since July 2026 and is a physician executive with extensive experience in the biotechnology and pharmaceutical industries. Immediately prior to joining the Company, she served as Clinical Head, Associate Vice President, Insulin and Glucagon Franchise at Eli Lilly and Company since 2021. In that role, she oversaw clinical development activities for Lilly's insulin and glucagon portfolio, including late stage development programs for efsitora, a once weekly insulin candidate, as well as other diabetes and metabolic disease therapies. Prior to assuming that position, Dr. Carr served as Senior Medical Fellow, Associate Vice President, Diabetes Business Development and External Innovation at Eli Lilly and Company from 2018 to 2021, where she led the evaluation of external business development opportunities and supported licensing and strategic transactions in diabetes and related metabolic diseases. Before joining Eli Lilly, Dr. Carr held positions of increasing responsibility at GlaxoSmithKline plc, including Endocrine Scientific Lead, Metabolic Pathways & Cardiovascular R&D Unit, and Global Medical Affairs Lead for albiglutide. Earlier in her career, she served in clinical development and medical leadership roles at CSL Behring and Wyeth LLC and held academic appointments in endocrinology and metabolism at Northwestern University, the University of Washington, and the University of Pennsylvania. Dr. Carr received a B.A. in Biology from Barnard College and an M.D. from Columbia College of Physicians and Surgeons. She is board certified in Endocrinology, Diabetes and Metabolism and Internal Medicine.- Molly Carr自2026年7月起担任iBio, Inc.的首席医疗官，是一名医师主管，在生物技术和制药行业拥有丰富经验。就在加入公司之前，她自2021年起在礼来公司担任胰岛素和胰高血糖素特许经营临床主管、副总裁。在担任该职务期间，她负责监督礼来公司胰岛素和胰高血糖素产品组合的临床开发活动，包括每周一次的胰岛素候选药物efitora的后期开发项目，以及其他糖尿病和代谢性疾病疗法。在担任该职位之前，Carr博士曾于2018年至2021年在礼来公司担任高级医学研究员、糖尿病业务发展和外部创新副总裁，在那里她领导了外部业务发展机会的评估，并支持糖尿病和相关代谢疾病的许可和战略交易。在加入礼来之前，Carl博士在葛兰素史克公司担任的职务越来越重要，包括内分泌科学主管、代谢途径和心血管研发部门，以及阿必鲁肽全球医疗事务主管。在她职业生涯的早期，她曾在CSL Behring和Wyeth LLC担任临床开发和医学领导职务，并在西北大学、华盛顿大学和宾夕法尼亚大学担任内分泌学和新陈代谢领域的学术职务。卡尔博士获得了巴纳德学院的生物学学士学位和哥伦比亚内科医生和外科医生学院的医学博士学位。她获得了内分泌学、糖尿病和代谢以及内科的董事会认证。
- Molly Carr has served as Ibio, Inc.'s Chief Medical Officer since July 2026 and is a physician executive with extensive experience in the biotechnology and pharmaceutical industries. Immediately prior to joining the Company, she served as Clinical Head, Associate Vice President, Insulin and Glucagon Franchise at Eli Lilly and Company since 2021. In that role, she oversaw clinical development activities for Lilly's insulin and glucagon portfolio, including late stage development programs for efsitora, a once weekly insulin candidate, as well as other diabetes and metabolic disease therapies. Prior to assuming that position, Dr. Carr served as Senior Medical Fellow, Associate Vice President, Diabetes Business Development and External Innovation at Eli Lilly and Company from 2018 to 2021, where she led the evaluation of external business development opportunities and supported licensing and strategic transactions in diabetes and related metabolic diseases. Before joining Eli Lilly, Dr. Carr held positions of increasing responsibility at GlaxoSmithKline plc, including Endocrine Scientific Lead, Metabolic Pathways & Cardiovascular R&D Unit, and Global Medical Affairs Lead for albiglutide. Earlier in her career, she served in clinical development and medical leadership roles at CSL Behring and Wyeth LLC and held academic appointments in endocrinology and metabolism at Northwestern University, the University of Washington, and the University of Pennsylvania. Dr. Carr received a B.A. in Biology from Barnard College and an M.D. from Columbia College of Physicians and Surgeons. She is board certified in Endocrinology, Diabetes and Metabolism and Internal Medicine.